Sugi Predict

Sugi Predict / Compounds / SCHEMBL1766161

SCHEMBL1766161

SCHEMBL1766161

COc1ccc(N)c(F)c1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.45
▸ EP300 Q09472 1/20 0.44
▸ KAT8 Q9H7Z6 1/20 0.44
▸ ALDH1A1 P00352 8/20 0.43
▸ CYP3A4 P08684 3/20 0.43
▸ TDP1 Q9NUW8 3/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ ADRA2B P18089 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ THRB P10828 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ TUBB4A P04350 5/20 0.41
▸ TUBB P07437 5/20 0.41
▸ TUBA3C P0DPH7 5/20 0.41
▸ TUBA1B P68363 5/20 0.41
▸ TUBA4A P68366 5/20 0.41
▸ TUBB4B P68371 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12074163 0.84 ALOX5AP (0.39) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL34472485 0.83 MAPT (0.35) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL1429267 0.83 IDO1 (0.45) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL29689187 0.83 IDO1 (0.45) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL1429875 0.82 IDO1 (0.48) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL633227 0.80 MEP1B (0.37) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL28133430 0.80 IDO1 (0.47) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL1122902 0.79 IDO1 (0.50) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL13862135 0.78 TUBB4A (0.39) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL2909998 0.77 PDE4A (0.45) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4667458-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG Kanaph Therapeutics Inc. (KR) 2025-12-24 — — EP disclosed
US-20240400518-A1 SOS1 INHIBITOR AND USE THEREOF CYRUS THERAPEUTICS INC. (KR) 2024-12-05 — — US disclosed
WO-2024172631-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG 주식회사 카나프테라퓨틱스 2024-08-22 — — WO disclosed
EP-4389738-A1 SOS1 INHIBITOR AND USE THEREOF Kanaph Therapeutics Inc. (KR) 2024-06-26 — — EP disclosed
CN-118119600-A SOS1 inhibitors and uses thereof 治纳辅医药科技有限公司 2024-05-31 — — CN disclosed
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY SPERMATECH AS (NO) 2023-08-24 — — US disclosed
US-20230074558-A1 DIMERIC COMPOUNDS AS STING AGONISTS MERSANA THERAPEUTICS, INC. 2023-03-09 — — US disclosed
WO-2023022497-A1 SOS1 INHIBITOR AND USE THEREOF 주식회사 카나프테라퓨틱스 2023-02-23 — — WO disclosed
WO-2023022497-A1 SOS1 INHIBITOR AND USE THEREOF 주식회사 카나프테라퓨틱스 2023-02-23 — — WO disclosed
EP-4069683-A1 DIMERIC COMPOUNDS AS STING AGONISTS Mersana Therapeutics, Inc. (US) 2022-10-12 — — EP disclosed
US-9340556-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2016-05-17 — — US disclosed
US-9340556-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2016-05-17 — — US disclosed
CN-104039152-A Antibacterial compounds GLAXO GROUP LTD 2014-09-10 — — CN disclosed
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-09-04 — — US disclosed
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-09-04 — — US disclosed
EP-2763539-A1 ANTIBACTERIAL COMPOUNDS Glaxo Group Limited (GB) 2014-08-13 — — EP disclosed
WO-2013052568-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-04-11 — — WO disclosed
WO-2013052568-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-04-11 — — WO disclosed
US-20110104055-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2011-05-05 — — US disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES IAPP, SNCA, BACE2 IDO1 223/4885EP300 1627/4885KAT8 3870/4885
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY NR5A1, NR1I3, NR5A2 IDO1 910/4885EP300 2102/4885KAT8 1201/4885
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS MRPL21, PEPD, ABCB11 IDO1 3254/4885EP300 2603/4885KAT8 3560/4885
US-20110104055-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES IAPP, SNCA, BACE2 IDO1 214/4885EP300 1612/4885KAT8 3981/4885
US-20230074558-A1 DIMERIC COMPOUNDS AS STING AGONISTS STING1, CGAS, MAVS IDO1 1655/4885EP300 4521/4885KAT8 4000/4885
US-20240400518-A1 SOS1 INHIBITOR AND USE THEREOF SOS1, RAC1, SOS2 IDO1 4188/4885EP300 4413/4885KAT8 4796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.